Introduction: Tadalafil is efficacious and well tolerated for erectile dysfunction (ED), but effects in men with "complete ED" are unclear.
Aim: To investigate effects of once-daily tadalafil in men with no successful intercourse attempts at baseline.
Methods: Through a post hoc, pooled-data analysis of four randomized, double-blind trials on the effects of tadalafil 2.5 or 5 mg (vs. placebo) in men with ED, we evaluated efficacy and safety in subjects with 0 "yes" responses to Sexual Encounter Profile question 3 (SEP3) during an initial 4-week treatment-free run-in period.
Main Outcome Measures: Changes from baseline in the SEP diary and the International Index of Erectile Function-erectile function (IIEF-EF) domain were subjected to analysis of covariance models.
Results: Five hundred ninety-five subjects with no successful attempts at baseline were included in the analysis. The mean (±standard deviation) age was 58.2 ± 10.7 years; and most subjects had ED for ≥1 year (95.0%). ED was severe in 61.5% and moderate in 26.4%. Approximately 45% had diabetes mellitus or hypertension. After 12 weeks, the mean per-patient SEP3 percentage increased from 0% to 32.4% with tadalafil 2.5 mg and to 46.4% with tadalafil 5 mg (each P < 0.001 vs. placebo). Corresponding data for successful penetration (SEP2) were increases from 21.1% to 48.2% with tadalafil 2.5 mg and from 24.4% to 66.2% with 5 mg (each P < 0.001 vs. placebo). Mean IIEF-EF increased from 9.7 to 15.7 with tadalafil 2.5 mg and from 10.7 to 19.2 with 5 mg (each P < 0.001 vs. placebo). Tadalafil also significantly improved the intercourse-satisfaction and overall-satisfaction domains (vs. placebo). Both doses of tadalafil were generally well tolerated, with adverse event rates similar to placebo.
Conclusions: The posttreatment intercourse success rate was 32% and 46% for tadalafil 2.5 mg and 5 mg, respectively, in men with no successful intercourse attempts at baseline.
Written by:
Shabsigh R, Seftel AD, Kim ED, Ni X, Burns PR. Are you the author?
Division of Urology, Maimonides Medical Center, New York, NY, USA; Division of Urology, Urology Residency Training Program, Cooper Medical School of Rowan University, Camden, NJ, USA; Division of Urology, Department of Surgery, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA; Lilly Research Laboratories, Eli Lilly and Company (Lilly USA, LLC), Indianapolis, IN, USA.
Reference: J Sex Med. 2012 Oct 4. Epub ahead of print.
doi: 10.1111/j.1743-6109.2012.02898.x
PubMed Abstract
PMID: 23035781
UroToday.com Erectile Dysfunction Section
